60601-36-7

Upstream product

• 118997-11-8 2-propylidenhydrazinecarboxylic acid benzyl ester 
• 5331-43-1 N-benzyloxycarbonyl-hydrazine 
• 123-38-6 propionaldehyde 

Downstream Products

• 63881-42-5 (N'-Benzyloxycarbonyl-N-propyl-hydrazino)-phenyl-acetic acid 
• 258526-02-2 2-benzyl-1-(tert-butyl)-1-propylhydrazine-1,2-dicarboxylate 

Relevant academic research and scientific papers

Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia in Vivo

As "Michael acceptors"may induce promiscuous responses in mammalian cells by reacting with various proteins, we modified the cinnamamide of our previous hydrazide-based HDAC inhibitors (HDACIs) to deactivate the Michael reaction. Representative compound 11h is 2-5 times more potent than lead compound 17 in both HDAC inhibitory activity (IC50 = 0.43-3.01 nM) and cell-based antitumor assay (IC50 = 19.23-61.04 nM). The breakthrough in the pharmacokinetic profile of 11h (oral bioavailability: 112%) makes it a lead-in-class oral active agent, validated in the in vivo anti-AML study (4 mg/kg p.o., TGI = 78.9%). Accumulated AcHH3 and AcHH4 levels in tumor tissue directly correlate with the in vivo efficacy, as panobinostat with lower AcHH3 and AcHH4 levels than 11h displays limited activity. To the best of our knowledge, this work contributes the first report of in vivo antitumor activity of hydrazide-based HDACIs. The outstanding pharmacokinetic/pharmacodynamic and antitumor activity of 11h could potentially extend the clinical application of current HDACIs.

E-64c-hydrazide: A lead structure for the development of irreversible cathepsinc inhibitors

CathepsinC is a papain-like cysteine protease with dipeptidyl aminopeptidase activity that is thought to activate various granule-associated serine proteases. Its exopeptidase activity is structurally explained by the so-called exclusion domain, which blocks the active-site cleft beyond the S2 site and, with its Asp1 residue, provides an anchoring point for the Nterminus of peptide and protein substrates. Here, the hydrazide of (2S,3S)-trans-epoxysuccinyl-L-leucylamido-3-methylbutane (E-64c) (k2/Ki=140±5M-1s-1) is demonstrated to be a lead structure for the development of irreversible cathepsinC inhibitors. The distal amino group of the hydrazide moiety addresses the acidic Asp1 residue at the entrance of the S2 pocket by hydrogen bonding while also occupying the flat hydrophobic S1′-S2′ area with its leucine-isoamylamide moiety. Furthermore, structure-activity relationship studies revealed that functionalization of this distal amino group with alkyl residues can be used to occupy the conserved hydrophobic S2 pocket. In particular, the n-butyl derivative was identified as the most potent inhibitor of the series (k2/Ki=56000±1700M-1s-1).

Orthogonal regioselective synthesis of N-alkyl-3-substituted tetrahydroindazolones

A divergent strategy for the regioselective and orthogonal synthesis of complementary regioisomers of N-alkyl-3-substituted-tetrahydroindazolones 3 and 4 was achieved from. Boc-protected alkylhydrazmes 1. The robustness and sub-strate generality of this method were validated by synthesizing 3 and. 4 through the intra- and intermolecular condensation of 1 with various 2-acylcyclohexane-l,3-diones 2 and aldehydes, respectively.

Novel azapeptide inhibitors of hepatitis C virus serine protease

Azapeptides are known inhibitors of several serine and cysteine proteases. In seeking different classes of inhibitors for the HCV serine protease, a series of novel azapeptide-based inhibitors were investigated which incorporated noncleavable P1/P1′ aza-a

Synthesis of new alpha-hydrazinoarylacetic acids and derivatives.

The synthesis of some alpha-hydrazinoarylacetic acids (I) by reaction of alpha-bromoarylacetic acids with hydrazine, alkylhydrazines and carbobenzyloxyhydrazines is described. Reduction of the hydrazones of 2- and 3-thienylglyoxylic acids provided a gener